{
    "clinical_study": {
        "@rank": "163227", 
        "arm_group": [
            {
                "arm_group_label": "Group 1", 
                "arm_group_type": "Experimental", 
                "description": "Group 1 received single-drug (doxorubicin)transarterial chemoembolization."
            }, 
            {
                "arm_group_label": "Group 2", 
                "arm_group_type": "Experimental", 
                "description": "Group 2 received double-drug (doxorubicin and mitomycin C)transarterial chemoembolization"
            }, 
            {
                "arm_group_label": "Group 3", 
                "arm_group_type": "Experimental", 
                "description": "Group 3 were treated with triple-drug (doxorubicin, mitomycin C and gemcitabine)transarterial chemoembolization."
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate local tumor control and survival rate after repeated transarterial\n      chemoembolization(TACE) using three different protocols in hepatocellular carcinoma (HCC)\n      patients."
        }, 
        "brief_title": "Different Protocols for Repeated Transarterial Chemoembolization in the Treatment of Patients With Hepatocellular Carcinoma", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": "Liver Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Liver Neoplasms", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with histologically confirmed HCC with unresectable disease without\n             extrahepatic metastases;\n\n          -  HCC with no previous treatment;\n\n          -  age between 18 and 75 years;\n\n          -  Life expectancy of at least 8 weeks;\n\n          -  main tumor size greater than 5 cm;\n\n          -  adequate hematologic function (platelet count: >60 \u00d7 109 platelets/L; hemoglobin:\n             >90g/L; and prothrombin time: <3 seconds above control);\n\n          -  adequate renal function (serum creatinine: \u22641.5 \u00d7 upper limit of normal);\n\n          -  Child-Pugh classification A or B grade;\n\n          -  Barcelona Clinic Liver Cancer (BCLC) stage B or C;\n\n          -  Eastern Co-operative Group performance status of zero or one.\n\n        Exclusion Criteria:\n\n          -  a hypovascular tumor (defined as a tumor with all its parts less contrast-enhanced\n             than the nontumorous liver parenchyma on arterial phase computed tomography scans);\n\n          -  diffuse-type HCC;\n\n          -  evidence of hepatic decompensation including esophageal or gastric variceal bleeding\n             or hepatic encephalopathy;\n\n          -  severe underlying cardiac or renal diseases;\n\n          -  color Doppler ultrasonography showing portal vein tumor thrombosis with complete main\n             portal vein obstruction without cavernous transformation; or    obstructive jaundice."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "162", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02038296", 
            "org_study_id": "TAE001"
        }, 
        "intervention": {
            "arm_group_label": [
                "Group 1", 
                "Group 2", 
                "Group 3"
            ], 
            "intervention_name": "transarterial chemoembolization", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Hepatocellular carcinoma", 
            "Transarterial chemoembolization", 
            "Gemcitabine"
        ], 
        "lastchanged_date": "January 16, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Guangzhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "510080"
                }, 
                "name": "Department of Interventional Radiology; Cancer Center; Guangdong General Hospital"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "3", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Ethics Committee"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "overall survival", 
            "safety_issue": "Yes", 
            "time_frame": "1-2 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02038296"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Guangdong General Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Guangdong General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2008", 
        "study_design": "Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}